A Microfluidic System Coupling Amplified Nanofluidic Virion Purification and Mass Spectrometry for Detection of SARS-CoV-2

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2018
    2021
  • Known Financial Commitments (USD)

    $334,234
  • Funder

    National Institutes of Health (NIH)
  • Principal Investigator

    AARON T TIMPERMAN
  • Research Location

    United States of America
  • Lead Research Institution

    UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Diagnostics

  • Special Interest Tags

    Innovation

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

A Microfluidic System Coupling Amplified Nanofluidic Virion Purification and Mass Spectrometry forDetection of SARS-CoV-2There is an urgent need for new methods and alternative techniques for viral detection in response to the SARS-CoV-2 pandemic. A novel strategy is proposed for viral detection that purifies the virions with ananofluidic/microfluidic (NF/MF) system prior to protein analysis by mass spectrometry. The NF/MF purificationsystem and protein analysis are highly complementary to and a radical departure from existing approaches. TheNF/MF system addresses the fundamental challenge of rapid and efficient purification of virions from the hugebackground of human cells and biomolecules. This novel approach will enable mining of the rich information thatis contained in the protein structures of the virus. In contrast with most other approaches, this technology will becapable of detecting mutated strains of SARS-CoV-2 and emergent viruses.The performance of the novel NF/MF will be fully characterized for different clinical needs. First, the extractionefficiency of the NF/MF system and the limits of detection for the complete diagnostic system will be measured.Second, application specific data acquisition and analysis strategies will be developed for the MS that are tunedto: 1) achieve the best detection limits for diagnostic testing, and 2) to gain the greatest percentage of the viralproteome for enhanced diagnostics for patients with high-viral loads.In addition to the gains in capabilities, it is expected that performance, costs, and sample throughput will befavorable. It is anticipated that limits of detection of 10 virions or better will be achieved with sample throughputof a few thousand samples per day per system. The simplicity of the process and ease of automation will reducepersonnel costs. Only a few consumables will be used that are orthogonal to the supply chain for RNA basedmethods. Thus, this technique is highly complementary to RNA-based approaches and would reducevulnerability to supply chain disruption. It is anticipated that these figures of merit and the potential applicationsfor utilizing the structural information contained in the proteins has the potential to revolutionize viral diagnosticsin both short-term and long-term.